|
1
|
Young JL Jr and Miller RW: Incidence of
malignant tumors in U.S. children. J Pediatr. 86:254–258. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fagioli F, Biasin E, Mereuta OM, et al:
Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow
Transpl. 41:S131–S134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barker N: The canonical Wnt/beta-catenin
signalling pathway. Methods Mol Biol. 468:5–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Behrens J: Control of beta-catenin
signaling in tumor development. Ann NY Acad Sci. 910:21–35. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haydon RC, Deyrup A, Ishikawa A, et al:
Cytoplasmic and/or nuclear accumulations of the beta-catenin
protein is a frequent event in human osteosarcoma. Int J Cancer.
102:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iwaya K, Ogawa H, Kuroda M, Izumi M,
Ishida T and Mukai K: Cytoplasmic and/or nuclear staining of
beta-catenin is associated with lung metastasis. Clin Exp
Metastasis. 20:525–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: implications for therapy
in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sato MM, Nakashima A, Nashimoto M, Yawaka
Y and Tamura M: Bone morphogenetic protein-2 enhances
Wnt/beta-catenin signaling-induced osteoprotegerin expression.
Genes Cells. 14:141–153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh A and Morris RJ: The Yin and Yang of
bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev.
21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim M and Choe S: BMPs and their clinical
potentials. BMB Rep. 44:619–634. 2011. View Article : Google Scholar
|
|
13
|
Herrera B, van Dinther M, ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herrera B, García-Álvaro M, Cruz S, et al:
BMP9 is a proliferative and survival factor for human
hepatocellular carcinoma cells. PloS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye L, Kynaston H and Jiang WG: Bone
morphogenetic protein-9 induces apoptosis in prostate cancer cells,
the role of prostate apoptosis response-4. Mol Cancer Res.
6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Feng H, Ren W, et al: BMP9
inhibits the proliferation and invasiveness of breast cancer cells
MDA-MB-231. J Cancer Res Clin. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Wang W, Xu J, et al:
Dihydroartemisinin inhibits tumor growth of human osteosarcoma
cells by suppressing Wnt/β-catenin signaling. Oncol Rep.
30:1723–1730. 2013.PubMed/NCBI
|
|
18
|
Chen D, Zhao M and Mundy GR: Bone
morphogenetic proteins. Growth Factors. 22:233–241. 2004.
View Article : Google Scholar
|
|
19
|
Grcevic D, Kusec R, Kovacic N, et al: Bone
morphogenetic proteins and receptors are over-expressed in
bone-marrow cells of multiple myeloma patients and support myeloma
cells by inducing ID genes. Leukemia Res. 34:742–751. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Park P, Zhang H, et al: BMP-2
inhibits the tumorigenicity of cancer stem cells in human
osteosarcoma OS99-1 cell line. Cancer Biol Ther. 11:457–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang Q, Sun MH, Cheng H, et al:
Characterization of the distinct orthotopic bone-forming activity
of 14 BMPs using recombinant adenovirus-mediated gene delivery.
Gene Ther. 11:1312–1320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv Z, Yang D, Li J, et al: Bone
morphogenetic protein 9 overexpression reduces osteosarcoma cell
migration and invasion. Mol Cells. 36:119–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo J, Chen J, Deng Z-L, et al: Wnt
signaling and human diseases: what are the therapeutic
implications? Lab Invest. 87:97–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Flores RJ, Li Y, Yu A, et al: A systems
biology approach reveals common metastatic pathways in
osteosarcoma. BMC Syst Biol. 6:502012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Freeman TJ, Smith JJ, Chen X, et al:
Smad4-mediated signaling inhibits intestinal neoplasia by
inhibiting expression of β-catenin. Gastroenterology. 142:562–571.
2012.PubMed/NCBI
|
|
26
|
Neville-Webbe HL, Cross NA, Eaton CL, et
al: Osteoprotegerin (OPG) produced by bone marrow stromal cells
protects breast cancer cells from TRAIL-induced apoptosis. Breast
Cancer Res Treat. 86:269–279. 2004.PubMed/NCBI
|
|
27
|
Nyambo R, Cross N, Lippitt J, et al: Human
bone marrow stromal cells protect prostate cancer cells from
TRAIL-induced apoptosis. J Bone Miner Res. 19:1712–1721. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shipman CM and Croucher PI:
Osteoprotegerin is a soluble decoy receptor for tumor necrosis
factor-related apoptosis-inducing ligand/Apo2 ligand and can
function as a paracrine survival factor for human myeloma cells.
Cancer Res. 63:912–916. 2003.
|
|
29
|
Holen I, Cross SS, Neville-Webbe HL, et
al: Osteoprotegerin (OPG) expression by breast cancer cells in
vitro and breast tumours in vivo - a role in tumour cell survival?
Breast Cancer Res Treat. 92:207–215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fodde R and Brabletz T: Wnt/beta-catenin
signaling in cancer stemness and malignant behavior. Curr Opin Cell
Biol. 19:150–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Forde JE and Dale TC: Glycogen synthase
kinase 3: A key regulator of cellular fate. Cell Mol Life Sci.
64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Xing M, Zhu M, et al: Glycogen
synthase kinase 3 beta induces apoptosis in cancer cells through
increase of survivin nuclear localization. Cancer Lett. 272:91–101.
2008. View Article : Google Scholar : PubMed/NCBI
|
